Neoadjuvant therapy could improve survival outcomes of locally advanced biliary tract cancer by increasing opportunities for curative resection: a systematic review and meta-analysis

Author:

Fu Jialu1,Zhang Rui2,Zhang Dong2,Geng Zhimin2

Affiliation:

1. Second Affiliated Hospital of Xi'an Jiaotong University

2. First Affiliated Hospital of Xi'an Jiaotong University

Abstract

Abstract Background Neoadjuvant therapy (NAT) has been proposed as one of the promising treatment alternatives for biliary tract cancer (BTC). We report a systematic review and meta-analysis to determine the impact of NAT on survival of BTC patients. Methods We included studies evaluating neoadjuvant therapy (NAT) for BTC patients published before October 2020. Published data were extracted and computed into hazard ratios (HRs) for overall survival (OS). Subgroup analyses of benefit based on tumor subtypes and treatment modalities were specified. Data were weighted by generic inverse variance and pooled using fixed-effect or random-effect model. Results 16 studies involving 2512 patients were included in the systematic review. Single arm meta-analysis showed a pooled clinical benefit rate (CBR) of 72.86% and a curative resection rate of 37.73%. 9 studies comparing the survival of patients receiving NAT followed by curative resection (group 1) and patients receiving upfront curative resection (group 2) were included in the meta-analysis. Though patients receiving NAT were more progressive in tumor stages, there was no difference in OS between the two groups (pooled HR = 1.21; 95% CI: 0.86–1.70; P = 0.28). Intrahepatic cholangiocarcinoma (ICC) patients in the neoadjuvant group seemed to have a worse survival outcome compared to upfront curative resection group (pooled HR = 1.39; 95% CI: 1.08–1.80; P = 0.01) while extrahepatic cholangiocarcinoma (ECC) patients presented with a better survival outcome (pooled HR = 0.77; 95% CI: 0.43–1.37; P = 0.37). Those receiving NACRT (pooled HR = 0.63; 95% CI: 0.33–1.19; P = 0.16) derived greater benefit than NACT (pooled HR = 1.70; 95% CI: 1.23–2.35; P < 0.01). Conclusion For patients with non-metastatic locally advanced BTC, NAT could improve survival outcomes by increasing opportunities for curative resection to obtain a similar prognosis compared to those with initially resectable disease.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3